We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca (AZN) Closes Agreement for Eplontersen With Ionis
Read MoreHide Full Article
AstraZeneca PLC (AZN - Free Report) announced that it has closed the previously announced agreement with Ionis Pharmaceuticals, Inc. (IONS - Free Report) for developing and commercializing eplontersen. Formerly known as IONIS-TTR-LRx, eplontersen is Ionis’ investigational medicine being developed for the treatment of transthyretin amyloidosis, a progressive and fatal disease.
Earlier this month, AstraZeneca and Ionis announced the strategic collaboration to jointly develop eplontersen in the United States.
Per the deal, the companies will have joint development and commercialization rights for eplontersen in the United States, while AstraZeneca will have exclusive rights to commercialize it in the rest of the world except Latin America. Ionis will continue to manufacture and supply eplontersen for the existing clinical studies. AstraZeneca will be responsible for commercial supply, and record all sales generated under the agreement.
Per the terms of the deal, AstraZeneca will make an upfront payment of $200 million to Ionis. In addition, Ionis will also be entitled to receive up to $485 million in development and approval milestones, and up to $2.9 billion in sales-related milestone payments as well as royalties in the range of low double-digit to mid-twenties on net sales, upon potential approval.
The above transaction is not likely to have an impact on AstraZeneca’s financial guidance for 2021.
Shares of AstraZeneca have rallied 17.3% so far this year compared with the industry’s growth of 21.1%.
Image Source: Zacks Investment Research
AstraZeneca has engaged in external acquisitions and strategic collaborations to boost its pipeline. The Alexion buyout earlier this year strengthened its immunology franchise, adding several drugs that can boost the company’s top line. The acquisition diversified AstraZeneca’s portfolio, marking its foray into rare diseases an increasingly attractive field.
In addition to acquisitions, AstraZeneca is pursuing co-development deals with companies like Innate Pharma, FibroGen, Moderna and Daiichi Sankyo to boost its pipeline and diversify its portfolio. AstraZeneca also has a profit-sharing deal with Merck for Lynparza and Koselugo (selumetinib).
Zacks Rank & Stocks to Consider
AstraZeneca currently carries a Zacks Rank #4 (Sell).
GlaxoSmithKline’s earnings estimates have been revised 5.2% upward for 2021 and 3.2% for 2022 over the past 60 days. The stock has rallied 20.7% year to date.
GlaxoSmithKline’s earnings surpassed estimates in two of the trailing four quarters, missed the same once and matched it once.
Endo International’s earnings estimates have been revised 22.8% upward for 2021 and 1.8% for 2022 over the past 60 days.
Endo International’s earnings surpassed estimates in each of the trailing four quarters.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
AstraZeneca (AZN) Closes Agreement for Eplontersen With Ionis
AstraZeneca PLC (AZN - Free Report) announced that it has closed the previously announced agreement with Ionis Pharmaceuticals, Inc. (IONS - Free Report) for developing and commercializing eplontersen. Formerly known as IONIS-TTR-LRx, eplontersen is Ionis’ investigational medicine being developed for the treatment of transthyretin amyloidosis, a progressive and fatal disease.
Earlier this month, AstraZeneca and Ionis announced the strategic collaboration to jointly develop eplontersen in the United States.
Per the deal, the companies will have joint development and commercialization rights for eplontersen in the United States, while AstraZeneca will have exclusive rights to commercialize it in the rest of the world except Latin America. Ionis will continue to manufacture and supply eplontersen for the existing clinical studies. AstraZeneca will be responsible for commercial supply, and record all sales generated under the agreement.
Per the terms of the deal, AstraZeneca will make an upfront payment of $200 million to Ionis. In addition, Ionis will also be entitled to receive up to $485 million in development and approval milestones, and up to $2.9 billion in sales-related milestone payments as well as royalties in the range of low double-digit to mid-twenties on net sales, upon potential approval.
The above transaction is not likely to have an impact on AstraZeneca’s financial guidance for 2021.
Shares of AstraZeneca have rallied 17.3% so far this year compared with the industry’s growth of 21.1%.
AstraZeneca has engaged in external acquisitions and strategic collaborations to boost its pipeline. The Alexion buyout earlier this year strengthened its immunology franchise, adding several drugs that can boost the company’s top line. The acquisition diversified AstraZeneca’s portfolio, marking its foray into rare diseases an increasingly attractive field.
In addition to acquisitions, AstraZeneca is pursuing co-development deals with companies like Innate Pharma, FibroGen, Moderna and Daiichi Sankyo to boost its pipeline and diversify its portfolio. AstraZeneca also has a profit-sharing deal with Merck for Lynparza and Koselugo (selumetinib).
Zacks Rank & Stocks to Consider
AstraZeneca currently carries a Zacks Rank #4 (Sell).
Better-ranked stocks in the healthcare sector include GlaxoSmithKline plc (GSK - Free Report) and Endo International plc , both sporting a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GlaxoSmithKline’s earnings estimates have been revised 5.2% upward for 2021 and 3.2% for 2022 over the past 60 days. The stock has rallied 20.7% year to date.
GlaxoSmithKline’s earnings surpassed estimates in two of the trailing four quarters, missed the same once and matched it once.
Endo International’s earnings estimates have been revised 22.8% upward for 2021 and 1.8% for 2022 over the past 60 days.
Endo International’s earnings surpassed estimates in each of the trailing four quarters.